Get the latest news, insights, and market updates on EWTX (Edgewise Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Will Edgewise Therapeutics’ (EWTX) New CFO Mark a Shift in Its Commercial Strategy?
Edgewise Therapeutics announced on November 10, 2025, that Michael Nofi has been appointed as Chief Financial Officer, succeeding R. Michael Carruthers, who is retiring after leading the company’s financial operations. Mr. Nofi’s extensive background in guiding life sciences companies through late-stage development and commercial launches highlights Edgewise’s focus on strong financial leadership during a pivotal growth phase. Let's explore how Mr. Nofi's arrival as CFO shapes Edgewise... Nov 18, 2025 - $EWTX
Edgewise Therapeutics (EWTX) Reports Heightened R&D Activity in Q3 2025
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is one of the best small-cap biotech stocks to buy according to analysts. Edgewise Therapeutics, Inc. (NASDAQ:EWTX) reported its Q3 2025 results on November 6, 2025. The quarter marked continued advancement of its muscular dystrophy and cardiac programs. Meanwhile, its critical GRAND CANYON cohort for sevasemten in Becker muscular dystrophy remains […] Nov 17, 2025 - $EWTX
Edgewise Therapeutics Stock Earns RS Rating Upgrade
Edgewise Therapeutics stock now meets that criteria, with an increase from 80 to 88 Monday. Decades of market research shows that the stocks that go on to make the biggest gains often have an 80 or higher RS Rating as they launch their biggest climbs. Edgewise Therapeutics stock has been rallying since retaking its 200-day moving average. Nov 17, 2025 - $EWTX
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on November 10, 2025, Edgewise granted an inducement stock option to purchase a total of 262,500 shares of Edgewise's common stock and an award of inducement restricted stock units ("RSU award") covering a total of 43,750 shares of Edgewise's common stock to Michael Nov 12, 2025 - $EWTX
Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced the appointment of Michael Nofi, as Chief Financial Officer (CFO), effective November 10, 2025. Mr. Nofi joins Edgewise after serving as Chief Accounting Officer (CAO) at SpringWorks Therapeutics, Inc. Mr. Nofi will succeed Edgewise CFO, R. Michael Carruthers, who is retiring. Nov 10, 2025 - $EWTX
Edgewise Therapeutics (EWTX): Assessing Valuation Following Recent Share Price Volatility
Edgewise Therapeutics (EWTX) shares have caught some attention lately, especially following a stretch of sharp price swings. Investors are taking stock of its performance as they consider what might drive the next move for this biotech player. See our latest analysis for Edgewise Therapeutics. Edgewise Therapeutics has seen some wild price action lately, but zooming out tells a bigger story. Even with a strong 90-day share price return of 32.1%, the 1-year total shareholder return is still... Nov 9, 2025 - $EWTX
H.C. Wainwright Maintains a Buy on Edgewise Therapeutics (EWTX), Sets a $42 PT
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is one of the best small cap stocks with the highest upside. H.C. Wainwright analyst Joseph Pantginis maintained a buy rating and $42 price target on Edgewise Therapeutics, Inc. (NASDAQ:EWTX) on October 13, supporting the optimistic rating with the company’s promising developments in the treatment of Becker muscular dystrophy (BMD). The […] Oct 21, 2025 - $EWTX
How Investors May Respond To Edgewise Therapeutics (EWTX) Long-Term Sevasemten Data at World Muscle Congress
Edgewise Therapeutics presented long-term clinical results for sevasemten, its investigational oral treatment for Becker and Duchenne muscular dystrophies, at the 30th Annual Congress of the World Muscle Society in Vienna on October 8, 2025. This update, featuring data from the CANYON and MESA trials showing disease stabilization, could impact how future Phase 3 studies are planned and how regulatory agencies evaluate sevasemten. We’ll explore how the presentation of robust long-term data... Oct 9, 2025 - $EWTX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple